BARD1 Life Sciences — Shareholder Meeting (November 2017)
23 slides from BARD1 Life Sciences's shareholder meeting presentation, Nov 28, 2017
Slide 1: Transforming early cancer detection & prevention
Transforming early cancer detection & prevention AGM PRESENTATION 28 November 2017
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation has been prepared by BARD1 Life Sciences Limited (“BARD1” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information n
Slide 3: BARD1 Life Sciences (ASX:BD1)
3 BARD1 Life Sciences (ASX:BD1) ■ Medtech company focused on developing non-invasive diagnostics for early detection of cancer to save patients’ lives ■ Platform technology of BARD1 tumour markers with potential Dx and Rx applications across multiple cancers ■ Diagnostic tests in development for lun
Slide 4: Company Snapshot
4 Company Snapshot CORPORATE INFORMATION SHAREHOLDERS (@ 24/11/17) # SHARES % HOLDING Listed 20 June 2016 Irmgard Irminger* 108,252,420 14.59% Industry Biotechnology Tony Walker* 88,501,626 11.93% Products Cancer diagnostics Peter Lynton Gunzburg 29,835,004 4.02% Headquarters Perth, Australia Univer
Slide 5: FY2017 Highlights
5 FY2017 Highlights Results of Lung Cancer Study in 628 samples 15/05/17 Financial Results FY2017 (AUD) Signed Cancer Vaccine collaboration with IRH Revenue & other income $44,028 05/04/17 Operating expenses $2,218,320 Appointed Advisory Board Other non-cash expenses $129,879 member 20/07/17 Net Los
Slide 6: Platform Technology
6 Platform Technology ■ Normal cells express FL BARD1 protein that functions as a tumour suppressor to prevent cancer ■ Cancer cells express abnormal BARD1 isoforms that drive oncogenesis and are correlated with cancer progression & poor prognosis ■ BARD1 isoforms are immunogenic and induce BARD1 au
Slide 7: Development Pipeline
7 Development Pipeline ■ Pipeline of BARD1 diagnostics and therapeutics in development to diversify product risk and expand market opportunities DIAGNOSTICS ASSAY CLINICAL MARKETING PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT VALIDATION / APPROVAL Screening & ELISA Lung Cancer Risk (Blood)
Slide 8: BARD1 Diagnostics
8 BARD1 Diagnostics ■ BARD1 autoantibody (AAb) tests detect BARD1 AAbs against BARD1 isoforms in human blood ■ BARD1 algorithm combines multiple AAb measurements into a cancer score that identifies the presence or absence of a specific cancer Autoantibodies enable early detection of early to late-st
Slide 9: Lung Cancer
9 Lung Cancer ■ Lung Cancer is the leading cause of cancer deaths worldwide Lung Cancer 5-Year Survival Rates □ World: 1.82m new cases & 1.59m deaths pa □ US: 222,500 new cases & 155,870 deaths pa Overall 18% ■ Smoking is major risk factor in 85% cases ■ Poor overall 5-year survival of 18% since Sta
Slide 10: BARD1 Lung Cancer Test
10 BARD1 Lung Cancer Test BARD1 Lung Cancer Test is an ELISA-based blood test in development for early detection of lung cancer ■ Pilot studies completed showing high accuracy for detection ROC curve for BARD1-Lung of lung cancer with up to 80% sensitivity & 77% specificity, and promising results fo
Slide 11: Ovarian Cancer
11 Ovarian Cancer ■ Ovarian Cancer is the leading cause of Ovarian Cancer 5-Year Survival Rates gynecological cancer deaths □ World: 239K new cases & 152K deaths pa Overall 46% □ US: 22,440 new cases & 14,080 deaths pa ■ Highest risk in post-menopausal women Stage 1 90% over 50 years & hereditary pr
Slide 12: BARD1 Ovarian Cancer Test
12 BARD1 Ovarian Cancer Test BARD1 Ovarian Cancer Test is an ELISA-based blood test in development for early detection of ovarian cancer ■ Pilot studies completed showing high accuracy for detection ROC curve for BARD1-Ovarian Model fitted to clean.ovca348 of ovarian cancer with up to 92% sensitivit
Slide 13: BARD1 Research
13 BARD1 Research Expand BARD1 diagnostic pipeline for other cancers •Evaluate BARD1 autoantibody (AAb) tests for other cancers including prostate & breast cancers •Investigate BARD1 RNA test for prediction of cancer progression in premalignant human specimens Evaluate BARD1 therapeutic applications
Slide 14: Large Market Opportunities
14 Large Market Opportunities $24B Lung Ca ■ Global cancer diagnostics market US$101B1 $7B Ovarian Ca US market opportunities for screening tests2 Lung Cancer screening test Ovarian Cancer screening test 6.8M eligible current / 43.2M average-risk former smokers 55-77y3 women 50-74 years4 Ave reimbur
Slide 15: Commercialisation Strategy
15 Commercialisation Strategy ▪Technical Validation on a commercial platform to demonstrate technical performance Lung ▪Clinical Validation to demonstrate clinical performance ▪Market first as laboratory developed tests (LDTs), then as invitro diagnostic (IVD) kits in US, EU and elsewhere Ovarian ▪C
Slide 16: Intellectual Property Portfolio
16 Intellectual Property Portfolio ■ 5 patent families covering various BARD1 DNA & protein sequences, methods of diagnosis & treatment, and use in multiple cancers Patent Family Title Granted Pending Expiry 5 6 20 PCT/FR01/02731 Truncated BARD1 protein and its US, JP 2023* diagnostic and therapeuti
Slide 17: Leadership Team
17 Leadership Team PETER GUNZBURG BCom | Chairman Public company director, stockbroker & technology investor, with 20+ years corporate advisory, capital raising, transaction & business management experience. Currently Chair of the Institute for Respiratory Health at UWA. Previously Director of Resol
Slide 18: Anticipated Milestones
18 Anticipated Milestones Date Events (CY) 4Q17 o Results of OC400 Study 1H18 o Initiate additional development studies for BARD1 Ovarian Cancer Test 2H18 o Initiate additional development studies for BARD1 Lung Cancer Test o Complete Technical Validation of BARD1 Test o Results of Cancer Vaccine an
Slide 19: Investment Summary
19 Investment Summary Compelling Opportunity Non-invasive cancer diagnostics targeting unmet needs in US$101B global market BARD1 autoantibody tests demonstrated as highly sensitive and specific for POC Completed detection of lung and ovarian cancers BARD1 Tests undergoing further development and va
Slide 20: Contacts
20 Contacts BARD1 Life Sciences Ltd Ground, Tempo Building, 431 Roberts Rd Subiaco WA 6008 Australia P +61 8 9381 9550 | E info@bard1.com | W www.bard1.com Dr Leearne Hinch | CEO | E leearne@bard1.com Dr Irmgard Irminger-Finger | CSO | E irmgard@bard1.com
Slide 21: Income Statement for year ended 30 June 2017
21 Income Statement for year ended 30 June 2017 30-Jun-17 30-Jun-16 Revenue & other income 44,028 Employee benefits expense (701,669) (13,673) R&D expense (1,089,976) Patent expenses (131,187) Administration costs (575,252) (109,763) Depreciation expense (8,008) (4,253) Movement in fair value of inv
Slide 22: Balance Statement for year ended 30 June 2017
22 Balance Statement for year ended 30 June 2017 30-Jun-17 30-Jun-16 Current Assets Cash & cash equivalents 650,051 3,097,751 Trade & other receivables 31,956 76,412 Held for trading assets 16,659 25,649 Total Current Assets 698,666 3,199,812 Non-Current Assets Property, plant & equipment 8,008 Fina
Slide 23: Acronyms
23 Acronyms Accuracy Percentage of true results correctly identified by a diagnostic test AUC Area Under the Curve is an index of the accuracy of a diagnostic test to discriminate between diseased and healthy states Biomarker Biological marker of disease state CE Mark Conformite Européene mark certi
BARD1 Life Sciences — Shareholder Meeting (November 2017) on 6ix